User: Guest  Login
Author(s):
Lux, Michael P.; Wöckel, Achim; Benedict, Agnes; Buchholz, Stefan; Kreif, No'emi; Harbeck, Nadia; Kreienberg, Rolf; Kaufmann, Manfred; Beckmann, Matthias W.; Jonat, Walter; Hadji, Peyman; Distler, Wolfgang; Raab, Guenther; Tesch, Hans; Weyers, Georg; Possinger, Kurt; Schneeweiss, Andreas 
Title:
Cost-Effectiveness Analysis of Anastrozole versus Tamoxifen in Adjuvant Therapy for Early-Stage Breast Cancer -- A Health-Economic Analysis Based on the 100-Month Analysis of the ATAC Trial and the German Health System 
Abstract:
Background: In the Arimidex, Tamoxifen Alone or in Combination (ATAC) trial, the aromatase inhibitor (AI) anastrozole had a significantly better efficacy and safety profile than tamoxifen as initial adjuvant therapy for hormone receptor-positive (HR+) early breast cancer (EBC) in postmenopausal patients. To compare the combined long-term clinical and economic benefits, we carried out a cost-effectiveness analysis (CEA) of anastrozole versus tamoxifen based on the data of the 100month analysis of...    »
 
Keywords:
Tamoxifen; QALY; Anastrozole; Cost-effectiveness analysis; Cost-utility analysis; Incremental cost-effectiveness ratio 
Journal title:
Onkologie 
Year:
2010 
Journal volume:
33 
Journal issue:
Pages contribution:
155--166 
Publisher:
S. Karger GmbH 
Publisher address:
Freiburg, Germany 
Print-ISSN:
1423-0240 
E-ISSN:
2296-5262 
Notes:
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich. This publication is with permission of the rights owner freely accessible due to an Alliance licence and a national licence (funded by the DFG, German Research Foundation) respectively.